HLN vs PBH: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
HLN is the larger of the two ($39.66B market cap): the incumbent the market prices for continued execution (14.95x forward earnings, beta 0.29). PBH is the smaller challenger ($2.06B), cheaper on forward earnings (8.54x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
HLN vs PBH: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | HLN | PBH | What it tells you |
|---|---|---|---|
| Market cap | $39.66B | $2.06B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 14.95 | 8.54 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 18.44 | 13.41 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.29 | 0.29 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 22% of range | 6% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.83 | 1.06 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: PBH is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how HLN and PBH affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HLN and PBH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HLN and PBH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Haleon plc (HLN) do?
Haleon plc is one of the world's largest standalone consumer-health companies, created when GSK demerged its consumer division in 2022. It sells everyday over-the-counter products across five categories: Oral Health (Sensodyne, parodontax, Polident), Pain Relief (Advil, Panadol, Voltaren, Excedrin), Respiratory Health (Theraflu, Otrivin), Vitamins, Minerals and Supplements (Centrum, Emergen-C), and Digestive Health and Therapeutic Skin Health (Tums, Fenistil). The company generated roughly 11 billion pounds (about ~$14 billion) of revenue in 2025 and about 11.15 billion pounds over the twelve months to June 2026, and holds leading or top-tier positions in many of its categories, which gives it pricing power and broad global distribution across pharmacy, grocery, and e-commerce channels.
What does Prestige Consumer Healthcare (PBH) do?
Prestige Consumer Healthcare Inc. owns over-the-counter healthcare brands rather than inventing them. The portfolio spans Monistat and Summer's Eve in women's health, BC and Goody's pain powders, Clear Eyes and TheraTears eye care, Dramamine, Fleet, Chloraseptic, Luden's, DenTek, Compound W, Nix, Debrox and Boudreaux's Butt Paste, plus Gaviscon in Canada and Hydralyte and the newly acquired Dermal Therapy line in Australia. Most manufacturing is outsourced, so spending goes to advertising and shelf presence instead of factories. Two segments carry the results: North American OTC Healthcare produced about $226 million of the June 2026 quarter's roughly $266 million, and International OTC Healthcare the remaining $40 million. Concentration is real on both ends, with the top five brands at about 39 percent of gross revenue, Walmart at roughly 19 percent and Amazon at roughly 16 percent. The fiscal year ends in March, so the quarter reported on August 6, 2026 was the first of fiscal 2027.
HLN vs PBH: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- HLN drivers: Oral Health leadership; Margin expansion and cash returns.
- PBH drivers: The biggest acquisition in years just closed; Organic growth returned, reported gross margin did not.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Organic growth has run at the low end of category norms (about 3% in 2025), pressured by a weak cold and flu season and soft North American consumer confidence, and J.P. For PBH, clear Eyes supply remains unreliable, and the Pillar5 remediation intended to fix it is a live drag on gross margin rather than a completed project.
HLN or PBH: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick HLN if you believe its drivers more; PBH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HLN and PBH guides.
HLN vs PBH: the full fundamentals
HLN. Haleon trades at about 20 times trailing and 16 times forward earnings, broadly in line with large consumer-staples peers, which prices in its defensive, cash-generative profile rather than a growth premium. Management guides to 3-5% organic revenue growth for 2026, but analyst tracking points to the bottom of that range, and the five covering analysts in the US data carry a mean ADR target near $11.93. The Q3 trading update on October 29, 2026 is the next read; figures are approximate and vary with currency and reporting conventions for the ADR.
PBH. Fiscal 2026, which ended March 31, 2026, brought revenue of about $1,088.7 million against about $1,137.8 million the year before, so the trailing figure reflects a down year already in the base. At about 14 times trailing and 10 times forward earnings as of October 16, 2026, the stock looks undemanding next to consumer staples generally, and the reason is visible on the balance sheet: enterprise value including roughly $2.0 billion of net debt is a very different number from the roughly $2.37 billion equity value. Guidance for fiscal 2027 is not comparable to fiscal 2026 without adjustment, because it folds in two acquisitions that closed in June and July 2026; analysts expect the November 5 report to show about $329 million of revenue and $1.07 of adjusted EPS.
Headline figures (approximate, October 2026): HLN shows revenue (ttm) ~£11.15B (FY2025 ~£11.0B, ~$14B), q2 2026 revenue ~£2.75B (latest-quarter growth ~2.2%), margins (ttm) ~66% gross, ~24% operating, ~15% net, net income (ttm) ~£1.6B; PBH shows revenue (ttm) ~$1.10B, through the quarter ended June 30, 2026, latest quarter (q1 fy2027) ~$265.7M revenue, up ~6.5%, with ~3.2% organic growth, diluted eps (q1 fy2027) ~$0.61 GAAP and ~$0.98 adjusted, versus ~$0.88 expected, margins and net income (ttm) Gross ~55%, operating ~21%; net income ~$172M.
The bottom line: HLN vs PBH
HLN and PBH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HLN and PBH exposure against your real portfolio. It is not an investment adviser.
Wondering how HLN or PBH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Haleon plc
Ask Walnut's AI anything about HLN and see how it fits what you own.
FAQ
What is the difference between HLN and PBH?
+
Haleon plc is one of the world's largest standalone consumer-health companies, created when GSK demerged its consumer division in 2022. Prestige Consumer Healthcare Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is HLN or PBH the better stock?
+
Neither is universally better. HLN is the larger incumbent; PBH is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, HLN or PBH?
+
On forward P/E (as of November 2026), HLN trades at 14.95x and PBH at 8.54x, so PBH is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both HLN and PBH?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of HLN vs PBH?
+
HLN: Organic growth has run at the low end of category norms (about 3% in 2025), pressured by a weak cold and flu season and soft North American consumer confidence, and J.P. Morgan's tracking puts 2026 at the bottom of the 3-5% guidance range again, so a slow-growth profile is a persistent concern; a reset of the 4-6% medium-term target in February 2027 is a live possibility. The Q4 outlook depends on the cold and flu season. The US pain market has been weak, weighing on Advil despite share gains. Haleon competes against far larger, deeper-pocketed rivals, faces private-label pressure, and carries meaningful debt from its demerger (about 8.3 billion pounds against roughly 0.8 billion of cash). As a UK-based company reporting in pounds, ADR holders are exposed to currency swings, and regulatory or product-liability issues in over-the-counter categories are an ongoing tail risk. PBH: Clear Eyes supply remains unreliable, and the Pillar5 remediation intended to fix it is a live drag on gross margin rather than a completed project. Net debt of roughly $2.0 billion now sits close to the entire equity market value, and first-quarter interest expense of about $13.9 million reflected only a few weeks of the new term loan, so the run-rate cost of that debt is materially higher from here. Customer concentration cuts both ways: Walmart was roughly 19 percent of gross revenue last quarter and Amazon roughly 16 percent, and Amazon also sells competing house-brand versions of several categories Prestige plays in. Private label and store brands, supplied at scale by Perrigo and sold as Equate, Up and Up and Amazon Basic Care, price against Prestige's brands directly whenever household budgets tighten. Several plaintiff law firms announced investigations after the May 13, 2026 fiscal 2026 results, though as of the Form 10-Q filed August 6, 2026 no securities class action with a case number had been filed and the company disclosed only routine legal matters. The stock has fallen about 18 percent in 2026 and trades well below the mean target of the five analysts who cover it (about $67.80), a gap that reflects doubt about how quickly the debt comes down.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell HLN or PBH; figures are approximate and dated (as of November 2026). Verify current data before investing.